These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26061031)

  • 1. With Cytometric Bead Assay, the Interleukin-10/HBV DNA Ratio Is an Early Predictor for Response to Interferon-α Treatment in Chronic Hepatitis B.
    Yan T; He Y; Li Y; Wang J; Chen T; Yang Y; Liu J; Jin L; Zhang Y; Yi R; Zhao Y
    J Interferon Cytokine Res; 2015 Oct; 35(10):779-84. PubMed ID: 26061031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
    van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
    J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.
    Li M; Gao Y; Yang L; Lin Y; Deng W; Jiang T; Bi X; Lu Y; Zhang L; Shen G; Liu R; Wu S; Chang M; Xu M; Hu L; Song R; Jiang Y; Yi W; Xie Y
    Front Immunol; 2022; 13():1024333. PubMed ID: 36203581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.
    Enomoto M; Nishiguchi S; Tamori A; Kozuka R; Hayashi T; Kohmoto MT; Jomura H; Morikawa H; Murakami Y; Shiomi S; Kawada N
    J Interferon Cytokine Res; 2015 Aug; 35(8):613-20. PubMed ID: 25884105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The relationship of serum HBsAg, HBeAg concentration and HBV-DNA load in chronic hepatitis B during IFN treatment].
    Li MH; Xie Y; Qiu GH; Lu Y; Zhao H; Yang M; Son SJ; Liu F; Zhang SF; Chen LJ; Cheng J; Xu DZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Feb; 25(1):26-8. PubMed ID: 21789848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
    Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
    Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
    Visvanathan K; Lang T; Ryan K; Wilson R; Skinner NA; Thompson AJ; Ahn SH; Weilert F; Abbott W; Gane E; Colledge D; Li K; Locarnini S; Mansell A; Revill PA
    J Viral Hepat; 2016 Mar; 23(3):170-9. PubMed ID: 26436722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.
    Ma Q; Qin B; Gong X; Lu X
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):820-4. PubMed ID: 23411867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
    J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.